Episode 268: ESMO 2023 - Enzalutamide and 177Lu-PSMA-617 in CRPC with Louise Emmett

The Uromigos - En podkast av The Uromigos

Prøv Podimo gratis i hele 60! dager!

I Podimo finner du eksklusive podkaster og bestselgende lydbøker tilpasset dine ører

Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)

Visit the podcast's native language site